Patents by Inventor Giuseppe Ciaramella

Giuseppe Ciaramella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EFFICACIOUS MRNA VACCINES
    Publication number: 20200254086
    Abstract: High quality vaccines are identified and formulated based on a threshold differential T-cell activation potential. The vaccines are mRNA vaccines formulated in a carrier, wherein the mRNA encodes an antigen.
    Type: Application
    Filed: August 17, 2018
    Publication date: August 13, 2020
    Applicant: Moderna TX, Inc.
    Inventors: Stephen Hoge, Giuseppe Ciaramella
  • HUMAN CYTOMEGALOVIRUS RNA VACCINES
    Publication number: 20200246453
    Abstract: The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: March 27, 2020
    Publication date: August 6, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
  • Human cytomegalovirus RNA vaccines
    Patent number: 10716846
    Abstract: The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: July 21, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Kambiz Mousavi
  • Nucleic acid vaccines
    Patent number: 10709779
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 14, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Axel Bouchon, Eric Yi-Chun Huang
  • CHIKV RNA vaccines
    Patent number: 10702597
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tal Zaks, Sunny Himansu, Sayda Mahgoub Elbashir
  • HPIV3 RNA vaccines
    Patent number: 10702599
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Betacoronavirus mRNA vaccine
    Patent number: 10702600
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Human cytomegalovirus vaccine
    Patent number: 10695419
    Abstract: The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: June 30, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John
  • RESPIRATORY VIRUS VACCINES
    Publication number: 20200197510
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Chikungunya virus RNA vaccines
    Patent number: 10675342
    Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: June 9, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
  • Zika virus MRNA vaccines
    Patent number: 10653767
    Abstract: Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: May 19, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • HERPES SIMPLEX VIRUS VACCINE
    Publication number: 20200129615
    Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.
    Type: Application
    Filed: March 15, 2018
    Publication date: April 30, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
  • RESPIRATORY SYNCYTIAL VIRUS VACCINE
    Publication number: 20200129608
    Abstract: The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: March 15, 2018
    Publication date: April 30, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Kapil Bahl, Amy Espeseth, Dai Wang, Andrew J. Bett
  • VARICELLA ZOSTER VIRUS (VZV) VACCINE
    Publication number: 20200069793
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.
    Type: Application
    Filed: March 15, 2018
    Publication date: March 5, 2020
    Applicant: ModernaTX, Inc.
    Inventor: Giuseppe Ciaramella
  • RESPIRATORY VIRUS NUCLEIC ACID VACCINES
    Publication number: 20200069794
    Abstract: Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovims (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPrV3) F protein.
    Type: Application
    Filed: December 8, 2017
    Publication date: March 5, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • HERPES SIMPLEX VIRUS VACCINE
    Publication number: 20200054737
    Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: April 25, 2018
    Publication date: February 20, 2020
    Applicant: Modema TX, Inc.
    Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
  • RNA BACTERIAL VACCINES
    Publication number: 20200038499
    Abstract: The disclosure relates to (i) a bacterial vaccine, comprising: at least one RNA polynucleotide having an open reading frame encoding at least one mutated bacterial antigenic polypeptide, wherein the mutated bacterial antigenic polypeptide comprises at least one asparagine (Asn) amino acid substitution; and (ii) a Streptococcal vaccine, comprising: at least one RNA polynucleotide having an open reading frame encoding at least one Streptococcal antigenic polypeptide, such as pneumolysin. Incorporating the RNA in a cationic lipid nanoparticle and a method of inducing an immune response with said vaccine are also disclosed.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 6, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Elisabeth Narayanan, Nadia Cohen, Giuseppe Ciaramella
  • ZOONOTIC DISEASE RNA VACCINES
    Publication number: 20200030432
    Abstract: The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Application
    Filed: March 16, 2018
    Publication date: January 30, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
  • hMPV RNA vaccines
    Patent number: 10543269
    Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: January 28, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu
  • Zika virus RNA vaccines
    Patent number: 10517940
    Abstract: The disclosure relates to Zika virus infection and the treatment thereof. The invention includes ribonucleic acid compositions, as well as methods of using the compositions for treating and preventing Zika virus infection.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: December 31, 2019
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks